Literature DB >> 20525842

Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial.

Iris Vilca1, Pablo Garcia Munitis, Angela Pistorio, Angelo Ravelli, Antonella Buoncompagni, Blanca Bica, Lucia Campos, Renate Häfner, Michael Hofer, Seza Ozen, Christian Huemer, Sang Cheol Bae, Flavio Sztajnbok, Olga Arguedas, Ivan Foeldvari, Hans Iko Huppertz, Maria Luz Gamir, Bo Magnusson, Frank Dressler, Yosef Uziel, Marion A J van Rossum, Peter Hollingworth, Gail Cawkwell, Alberto Martini, Nicolino Ruperto.   

Abstract

OBJECTIVES: To determine whether baseline demographic, clinical, articular and laboratory variables predict methotrexate (MTX) poor response in polyarticular-course juvenile idiopathic arthritis.
METHODS: Patients newly treated for 6 months with MTX enrolled in the Paediatric Rheumatology International Trials Organization (PRINTO) MTX trial. Bivariate and logistic regression analyses were used to identify baseline predictors of poor response according to the American College of Rheumatology pediatric (ACR-ped) 30 and 70 criteria.
RESULTS: In all, 405/563 (71.9%) of patients were women; median age at onset and disease duration were 4.3 and 1.4 years, respectively, with anti-nuclear antibody (ANA) detected in 259/537 (48.2%) patients. With multivariate logistic regression analysis, the most important determinants of ACR-ped 70 non-responders were: disease duration > 1.3 years (OR 1.93), ANA negativity (OR 1.77), Childhood Health Assessment Questionnaire (CHAQ) disability index > 1.125 (OR 1.65) and the presence of right and left wrist activity (OR 1.55). Predictors of ACR-ped 30 non-responders were: ANA negativity (OR 1.92), CHAQ disability index > 1.14 (OR 2.18) and a parent's evaluation of child's overall well-being < or = 4.69 (OR 2.2).
CONCLUSION: The subgroup of patients with longer disease duration, ANA negativity, higher disability and presence of wrist activity were significantly associated with a poorer response to a 6-month MTX course.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20525842     DOI: 10.1136/ard.2009.120840

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  20 in total

Review 1.  Defining juvenile idiopathic arthritis remission and optimum time for disease-modifying anti-rheumatic drug withdrawal: why we need a consensus.

Authors:  Thomas Broughton; Kate Armon
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

2.  Frequency of joint involvement in juvenile idiopathic arthritis during a 5-year follow-up of newly diagnosed patients: implications for MR imaging as outcome measure.

Authors:  Robert Hemke; Charlotte M Nusman; Désirée M F M van der Heijde; Andrea S Doria; Taco W Kuijpers; Mario Maas; Marion A J van Rossum
Journal:  Rheumatol Int       Date:  2014-08-14       Impact factor: 2.631

Review 3.  Advances in biomarkers for paediatric rheumatic diseases.

Authors:  Alessandro Consolaro; Giulia C Varnier; Alberto Martini; Angelo Ravelli
Journal:  Nat Rev Rheumatol       Date:  2014-12-16       Impact factor: 20.543

4.  Pixel-by-pixel analysis of DCE-MRI curve shape patterns in knees of active and inactive juvenile idiopathic arthritis patients.

Authors:  Robert Hemke; Cristina Lavini; Charlotte M Nusman; J Merlijn van den Berg; Koert M Dolman; Dieneke Schonenberg-Meinema; Marion A J van Rossum; Taco W Kuijpers; Mario Maas
Journal:  Eur Radiol       Date:  2014-04-26       Impact factor: 5.315

Review 5.  The advances of methotrexate resistance in rheumatoid arthritis.

Authors:  Jun Yu; Peng Zhou
Journal:  Inflammopharmacology       Date:  2020-08-05       Impact factor: 4.473

6.  The diagnostic accuracy of unenhanced MRI in the assessment of joint abnormalities in juvenile idiopathic arthritis.

Authors:  Robert Hemke; Taco W Kuijpers; J Merlijn van den Berg; Mira van Veenendaal; Koert M Dolman; Marion A J van Rossum; Mario Maas
Journal:  Eur Radiol       Date:  2013-02-01       Impact factor: 5.315

7.  Reliability and responsiveness of the Juvenile Arthritis MRI Scoring (JAMRIS) system for the knee.

Authors:  Robert Hemke; Marion A J van Rossum; Mira van Veenendaal; Maaike P Terra; Eline E Deurloo; Milko C de Jonge; J Merlijn van den Berg; Koert M Dolman; Taco W Kuijpers; Mario Maas
Journal:  Eur Radiol       Date:  2012-10-20       Impact factor: 5.315

Review 8.  Review: Genetics and the Classification of Arthritis in Adults and Children.

Authors:  Peter A Nigrovic; Soumya Raychaudhuri; Susan D Thompson
Journal:  Arthritis Rheumatol       Date:  2017-12-01       Impact factor: 10.995

9.  Contrast-enhanced MRI features in the early diagnosis of Juvenile Idiopathic Arthritis.

Authors:  Robert Hemke; Taco W Kuijpers; Charlotte M Nusman; Dieneke Schonenberg-Meinema; Marion A J van Rossum; Koert M Dolman; J Merlijn van den Berg; Mario Maas
Journal:  Eur Radiol       Date:  2015-05-23       Impact factor: 5.315

10.  Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand?

Authors:  Karina I Halilova; Elizabeth E Brown; Sarah L Morgan; S Louis Bridges; Min-Ho Hwang; Donna K Arnett; Maria I Danila
Journal:  Int J Rheumatol       Date:  2012-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.